Evidence map›Paper›PMID 35506263›Full record

ArticleDeutsches Arzteblatt international2022

Recommendations for the Outpatient Drug Treatment of Patients With COVID-19.

Hanna Kaduszkiewicz, Michael M Kochen, Stefan Kluge, Jakob J Malin, Stephanie Weibel, Nicole Skoetz, guideline group

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Deutsches Arzteblatt international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. [News from DEGAM and its Foundation].ZFA. Zeitschrift fur Allgemeinmedizin · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hanna KaduszkiewiczInstitute of General Medicine, Christian Albrechts University of Kiel; Emeritus, University Medical Center Göttingen; Institute of General Medicine, Faculty of Medicine, University Medical Center Freiburg; Department of Intensive Care Medicine, Hamburg-Eppendorf University Hospital; Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne; Medical Clinic and Polyclinic for Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, University Hospital of Würzburg; Department I of Internal Medicine, Evidence-Based Oncology, Faculty of Medicine and University Hospital of Cologne, University of Cologne; *See eBox for members of the guideline group and the consensus conference (collaborators).
Michael M Kochen
Stefan Kluge
Jakob J Malin
Stephanie Weibel
Nicole Skoetz
guideline group
Universität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOne of the purposes of outpatient treatment for COVID-19 patients is to prevent severe disease courses and hospitalization. There is a need for evidence-based recommendations to be applied in primary care and specialized outpatient settings.

methodsThis guideline was developed on the basis of publications that were retrieved by a systematic search for randomized controlled trials in the Cochrane COVID-19 trial registry. The quality of evidence was assessed with GRADE, and structured consensus generation was carried out with MAGICapp.

resultsUnvaccinated COVID-19 outpatients with at least one risk factor for a severe disease course may be treated in the early phase of the disease with sotrovimab, remdesivir, or nirmatrelvir/ritonavir. Molnupiravir may also be used for such patients if no other clinically appropriate treatment options are available. Immunosuppressed persons with COVID-19 who are at high risk, and whose response to vaccination is expected to be reduced, ought to be treated with sotrovimab. It should be noted, however, that the clinical efficacy of sotrovimab against infections with the omicron subtype BA.2 is uncertain at the currently used dose, as the drug has displayed reduced activity against this subtype in vitro. COVID-19 patients at risk of a severe course may be offered budesonide inhalation, according to an off-label recommendation of the German College of General Practitioners and Family Physicians (other medical societies do not recommend either for or against this treatment). Thrombo - embolism prophylaxis with low-molecular-weight heparin may be given to elderly patients or those with a pre-existing illness. No recommendation is made concerning fluvoxamine or colchicine. Acetylsalicylic acid, azithromycin, ivermectin, systemic steroids, and vitamin D should not be used for the outpatient treatment of COVID-19.

conclusionDrug treatment is now available for outpatients with COVID-19 in the early phase. Nearly all of the relevant trials have been conducted in unvaccinated subjects; this needs to be kept in mind in patient selection.

Indexed as

Ambulatory CareCOVID-19 Drug TreatmentPractice Guidelines as TopicAgedAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingHumansRandomized Controlled Trials as TopicSystematic Reviews as TopicTreatment OutcomeAntibodies, Monoclonal, HumanizedAntibodies, Neutralizingsotrovimab

Identifiers

PMID35506263
PMCPMC9468468
OpenAlexW4225307885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.